High-risk acute myelogenous leukemia: maintenance therapy with Azacitadine and Valproic acid after allogeneic stem cell transplant
Relapse is the major cause of failure after allogeneic stem cell transplantation ( Allo-SCT ) for acute myelogenous leukemia ( AML ). Allo-SCT for high risk acute myelogenous leukemia, defined by ...
Relapsed B-cell acute lymphoblastic leukemia: durability of CAR T-cell therapy response may depend on pretreatment disease burden
Although most patients with relapsed B-cell acute lymphoblastic leukemia ( B-ALL ) experienced complete response after treatment with a type of CAR T-cell immunotherapy, pretreatment disease burden im ...
Carfilzomib significantly improves overall survival compared to Bortezomib in relapsed or refractory multiple myeloma patients
Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were presented. The study met the key secondary endpoint of overall survival, demons ...
Pembrolizumab in combination with Pomalidomide and Dexamethasone for Pomalidomide exposed relapsed or refractory multiple myeloma
Modern therapy for multiple myeloma including generations of Thalidomide analogues, proteasome inhibitors and alkylating agents has substantially improved the survival for this disease. Patients who ...
Pembrolizumab in combination with Pomalidomide and Dexamethasone for relapsed / refractory multiple myeloma
Immunotherapy in multiple myeloma is emerging as an effective modality in therapy of multiple myeloma with the approval of several monoclonal antibodies and encouraging results for vaccines and T cell ...
Combination of Nivolumab or Ipilimumab with Azacitidine in patients with previously treated or untreated myelodysplastic syndromes
Outcomes of patients with myelodysplastic syndromes ( MDS ) after hypomethylating agent ( HMA ) failure remain poor. Improving the response and survival of patients with higher-risk myelodysplastic sy ...
Progression-free survival benefit in early relapsing multiple myeloma patients treated with Carfilzomib-based regimen
Data from a secondary analysis of the pivotal phase 3 ASPIRE trial that showed Carfilzomib ( Kyprolis ) for injection in combination with Lenalidomide ( Revlimid ) and Dexamethasone ( KRd) improved pr ...
Heavily pre-treated patients with relapsed or refractory classical Hodgkin lymphoma: Pembrolizumab, as a monotherapy, shows overall response rates of 73 to 83%, with complete response rates of 27 to 30%
The findings from KEYNOTE-087, the phase 2 study investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin l ...
Previously untreated follicular lymphoma: Obinutuzumab has shown superior progression-free survival compared to Rituximab
The results from the pivotal phase III GALLIUM trial in people with previously untreated follicular lymphoma, the most common type of indolent ( slow-growing ) non-Hodgkin lymphoma ( iNHL ), were anno ...
New therapeutic target: CDK4/ARK5 inhibition in multiple myeloma
Despite new therapies, multiple myeloma remains incurable causing most patients to ultimately develop drug resistance and succumb to the disease. The pursuit of drugs that inhibit cell cycle regulator ...
T-cell leukemia treatment: enzyme DLST, a new target
Researchers at Boston University have shown that T-cell leukemia cells use a particular cycle, called the TCA or Kreb cycle, to support their growth and survival. The findings which appear in the j ...
Weight and height during adolescence may be associated with future risk of developing non-Hodgkin's lymphoma
A new analysis has indicated that higher body weight and taller stature during adolescence increase the risk of developing non-Hodgkin's lymphoma ( NHL ), a type of cancer of the lymphatic system. T ...
Advanced-stage mantle cell lymphoma: 90Y-Ibritumomab-Tiuxetan consolidation therapy after first-line autologous stem cell transplantation
Mantle cell lymphoma ( MCL ) is an aggressive lymphoma with a dismal prognosis because of numerous relapses. Because the most promising results have been obtained with immunochemotherapy followed by ...
Acquired thrombotic thrombocytopenic purpura: significant reductions in time to platelet count normalisation and recurrences with Caplacizumab
The results of the phase II TITAN study with Caplacizumab for patients with acquired thrombotic thrombocytopenic purpura ( aTTP) have been published in The New England Journal of Medicine ( NEJM ). ...
Midostaurin improves overall survival by 23% in acute myeloid leukemia patients with FLT3 mutations
Positive results from the global phase III RATIFY ( CALGB 10603 ) clinical trial were announced. In the study, adult patients under 60 years of age with newly-diagnosed FLT3-mutated acute myeloid leuk ...
